pubmed· e01.org

PubMed · PMID 30865166

Atypical hemolytic uremic syndrome and complement blockade: established and emerging uses of complement inhibition.

PMID 30865166Journal Current opinion in nephrology and hypertensionYear 2019Authors 5DOI 10.1097/MNH.0000000000000499

  • Source PubMed
  • Journal Current opinion in nephrology and hypertension
  • Year 2019
  • Authors Ramy M Hanna; Marina Barsoum; Andrae Vandross; Ira Kurtz; Richard Burwick
  • Licence NLM/PubMed terms

Abstract

Atypical hemolytic uremic syndrome (aHUS) is a diagnosis that has captured the interest of specialists across multiple fields. The hallmark features of aHUS are microangiopathic hemolysis and thrombocytopenia, which creates a diagnostic dilemma because of the occurrence of these findings in a wide variety of clinical disorders.

In most of the instances, aHUS is a diagnosis of exclusion after ruling out causes such as Shigella toxin, acquired or genetic a disintegrin and metalloproteinase thrombospondin motif 13 deficiency (thrombotic thrombocytopenic purpura), and vitamin B12 deficiency. In the purest sense, aHUS is a genetic condition that is activated (or unmasked) by an environmental exposure. However, it is now evident that complement activation is a feature of many diseases.

Variants in complement regulatory genes predispose to microangiopathic hemolysis in many rheumatologic, oncologic, and drug-induced vascular, obstetric, peritransplant, and infectious syndromes. Many 'hemolysis syndromes' overlap clinically with aHUS, and we review the literature on the treatment of these conditions with complement inhibition. New reports on the treatment of C3 glomerulopathy, Shiga toxin-related classic hemolytic uremic syndrome, and medication-related thrombotic microangiopathy will be reviewed as well.

Record details

PMID30865166
PMCIDnot held
DOI10.1097/MNH.0000000000000499
JournalCurrent opinion in nephrology and hypertension
Year2019
AuthorsRamy M Hanna; Marina Barsoum; Andrae Vandross; Ira Kurtz; Richard Burwick
Licencenot stated
MeSHAtypical Hemolytic Uremic Syndrome; Complement Activation; Complement Inactivating Agents; Humans

Source record

Open the PubMed record. This page holds the abstract and citation fields for this PMID; no PMC full text is held for it.

Source
PubMed / NLM
PMID
30865166
Rendered
2026-11-22
Completeness
abstract and citation fields